In8bio Operating Income Over Time
| INAB Stock | USD 1.71 0.05 3.01% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out In8bio Performance and In8bio Correlation. Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of In8bio. Market participants price In8bio higher when confident in its future expansion prospects. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive In8bio assessment requires weighing all these inputs, though not all factors influence outcomes equally.
The market value of In8bio Inc is measured differently than its book value, which is the value of In8bio that is recorded on the company's balance sheet. Investors also form their own opinion of In8bio's value that differs from its market value or its book value, called intrinsic value, which is In8bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because In8bio's market value can be influenced by many factors that don't directly affect In8bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between In8bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if In8bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Meanwhile, In8bio's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Cross Equities Operating Income Analysis
Compare In8bio Inc and related stocks such as Transcode Therapeutics, Aptevo Therapeutics, and HCW Biologics Operating Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| RNAZ | (384 K) | (384 K) | (384 K) | (384 K) | (384 K) | (384 K) | (384 K) | (384 K) | (384 K) | (456.9 K) | (726.6 K) | (6.2 M) | (18.7 M) | (19.4 M) | (15.7 M) | (14.1 M) | (13.4 M) |
| APVO | (53.4 M) | (53.4 M) | (53.4 M) | (53.4 M) | (51.5 M) | (61.1 M) | (126.9 M) | (53.9 M) | (51.7 M) | (41 M) | (27.5 M) | (21.4 M) | (28.6 M) | (28.9 M) | (24.6 M) | (28.3 M) | (29.7 M) |
| HCWB | (7.4 M) | (7.4 M) | (7.4 M) | (7.4 M) | (7.4 M) | (7.4 M) | (7.4 M) | (7.4 M) | (7.4 M) | (7.4 M) | (5.8 M) | (13.4 M) | (15.1 M) | (25.7 M) | (29.5 M) | (26.5 M) | (25.2 M) |
| LYRA | (7.3 M) | (7.3 M) | (7.3 M) | (7.3 M) | (7.3 M) | (7.3 M) | (7.3 M) | (7.3 M) | (7.3 M) | (16.5 M) | (22.2 M) | (43.6 M) | (56.3 M) | (67.1 M) | (96.3 M) | (86.7 M) | (82.4 M) |
| KPRX | (5.9 M) | (5.9 M) | (5.9 M) | (3.1 M) | (2.5 M) | (6.7 M) | (13.3 M) | (14.6 M) | (10.8 M) | (7 M) | (6.9 M) | (14.2 M) | (12.3 M) | (12.6 M) | 4.5 M | 4.1 M | 4.3 M |
| GLTO | (12.9 M) | (12.9 M) | (12.9 M) | (12.9 M) | (12.9 M) | (12.9 M) | (12.9 M) | (12.9 M) | (12.9 M) | (39 M) | (33.6 M) | (52.2 M) | (61.2 M) | (39.9 M) | (22.3 M) | (20 M) | (21 M) |
| APRE | (3.2 M) | (21.3 K) | (21.3 K) | (246.5 K) | (15.9 M) | (15.9 M) | (15.9 M) | (15.9 M) | (16.5 M) | (29.5 M) | (52.8 M) | (37.4 M) | (113.4 M) | (15.5 M) | (14.3 M) | (12.9 M) | (13.5 M) |
| ACXP | (5.9 M) | (5.9 M) | (5.9 M) | (5.9 M) | (5.9 M) | (5.9 M) | (5.9 M) | (5.9 M) | (5.9 M) | (5.9 M) | (4.6 M) | (12.9 M) | (12.1 M) | (14.6 M) | (14.1 M) | (12.7 M) | (13.3 M) |
| BCDA | 206.2 K | (618 K) | (339 K) | 9 K | 231 K | 319 K | (7.6 M) | (12.4 M) | (14.1 M) | (14.2 M) | (15.5 M) | (12.6 M) | (11.9 M) | (11.6 M) | (8 M) | (7.2 M) | (6.8 M) |
| PHIO | (12.8 M) | (12.8 M) | (13 M) | (20.9 M) | (8.8 M) | (10.2 M) | (9 M) | (14.1 M) | (7.4 M) | (9 M) | (8.8 M) | (13.5 M) | (11.5 M) | (10.8 M) | (7.4 M) | (8.5 M) | (8.9 M) |
In8bio Inc and related stocks such as Transcode Therapeutics, Aptevo Therapeutics, and HCW Biologics Operating Income description
Operating Income is the amount of profit realized from In8bio Inc operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of In8bio Inc is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.My Equities
My Current Equities and Potential Positions
| In8bio Inc | INAB |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | 350 5th Avenue, |
| Exchange | NASDAQ Exchange |
USD 1.71
Check out In8bio Performance and In8bio Correlation. You can also try the Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.
In8bio technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.